Atkinson Edward Morrow III's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 26, 2026
- Accession no.
- 0000875320-26-000106
- Filed
- Feb 26, 2026
- Trade date
- Feb 24-25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $324.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atkinson Edward Morrow IIICIK 0001914164 | Officer (EVP, Chief Technical Ops. Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Common Stock | FTax withholdingDisposed | −1,627 | $485.11 | −$789,273.97 | 19,100 | Direct | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −668 | $486.35 | −$324,881.8 | 18,432 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.